Brokerages Set Korro Bio, Inc. (NASDAQ:KRRO) Price Target at $142.57

Korro Bio, Inc. (NASDAQ:KRRO) has received a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $142.57.

Several equities analysts recently commented on KRRO shares. Oppenheimer started coverage on Korro Bio in a research report on Friday, January 10th. They set an “outperform” rating and a $155.00 target price for the company. Royal Bank of Canada reduced their target price on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $115.00 target price on shares of Korro Bio in a research report on Thursday.

Hedge Funds Weigh In On Korro Bio

A number of hedge funds and other institutional investors have recently modified their holdings of KRRO. Alliancebernstein L.P. purchased a new position in shares of Korro Bio in the 4th quarter worth about $26,870,000. Driehaus Capital Management LLC boosted its holdings in shares of Korro Bio by 220.3% in the 4th quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company’s stock worth $18,841,000 after purchasing an additional 340,410 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Korro Bio in the 4th quarter worth about $3,887,000. Franklin Resources Inc. purchased a new stake in Korro Bio during the 4th quarter valued at about $3,493,000. Finally, Tri Locum Partners LP grew its position in Korro Bio by 125.3% during the 4th quarter. Tri Locum Partners LP now owns 144,216 shares of the company’s stock worth $5,490,000 after acquiring an additional 80,202 shares during the last quarter. 13.18% of the stock is currently owned by hedge funds and other institutional investors.

Korro Bio Trading Up 8.5 %

NASDAQ:KRRO opened at $23.76 on Thursday. Korro Bio has a 52-week low of $18.50 and a 52-week high of $98.00. The business’s fifty day moving average is $29.88 and its 200 day moving average is $41.37.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.33) by $0.07. The company had revenue of $2.27 million for the quarter. Research analysts forecast that Korro Bio will post -9.52 earnings per share for the current year.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).